You are here

ContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association for the Study of Liver Diseases

EDISON, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of liver disease arising from chronic viral infection and non-alcoholic steatohepatitis, today announced that it will present two posters at The Liver Meeting® 2018, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held in San Francisco, California from November 9-13, 2018.

The posters will address how CRV431, the Company’s cyclophilin inhibitor, may potentially benefit patients by reducing hepatitis B virus (“HBV”)-associated liver disease; and the pharmacokinetic and safety profile of ContraVir’s tenofovir exalidex (TXLTM) in patients with renal insufficiency.

Robert Foster, PharmD, PhD, Chief Executive Officer of ContraVir Pharmaceuticals, who will be presenting the posters said, “We are particularly excited to present data demonstrating CRV431’s ability to reduce characteristics of liver disease in an industry standard NASH animal model of HBV to clinicians and researchers at this prestigious scientific meeting. The findings suggest that CRV431 may benefit HBV patients not only via its antiviral activity, but by reducing liver disease such as fibrosis and hepatocellular carcinoma.”

Presentation Details

Presentation #1:  Pharmacokinetics of Tenofovir Exalidex (TXLTM) in Severe Renal Impairment: No Need for Dosage Adjustment
Publication Number:  0415
Authors:  M. Snyder, Julia Crombie, Daren Ure, Daniel Trepanier, Jill Greytok, Robert T. Foster
ContraVir Pharmaceuticals, Inc. 
Date:  Friday, November 9, 2018
Time:  Noon – 1:30 pm
Location:  Moscone Center North/South Building, Hall C

Presentation #2:  CRV431, a Cyclophilin Inhibitor, Reduces Fibrosis and Tumor Burden in Mice with Hepatocellular Carcinoma
Publication Number:  0418
Authors:  Joseph Kuo1, Michael Bobardt1, Udayan Chatterji1, Daniel Trepanier2, Daren Ure2, Philippe Gallay1, and Robert Foster2
1Immunology & Microbiology, The Scripps Research Institute,2ContraVir Pharmaceuticals, Inc.
Date:  Friday, November 9, 2018
Time:  Noon – 1:30 pm
Location:  Moscone Center North/South Building, Hall C

About CRV431

CRV431 is a non-immunosuppressive analog of cyclosporine A (CsA) whose primary biochemical action is inhibition of cyclophilin isomerase activity, playing a key role in protein folding. Other viruses such as HIV-1 and HCV, similarly use cyclophilin for their replication. In pre-clinical studies, CRV431 has shown potential in experimental models to complement current hepatitis B treatments by reducing multiple markers of infection including HBV DNA, HBsAg, HBx, HBeAg, and HBV uptake by cells. Studies have also demonstrated that CRV431 reduces the progression of fibrosis in an animal model and also reduces both the number and size of liver tumors in a hepatocellular carcinoma (HCC) model.


Tenofovir exalidex (TXL™) is a highly potent prodrug of the antiviral tenofovir. Tenofovir is the active component of both Vemlidy®(tenofovir alafenamide) and Viread® (tenofovir disoproxil fumarate).TXL™’s novel liver-targeting prodrug structure results in decreased systemic circulating levels of tenofovir, thereby reducing the potential for renal and bone side effects. ContraVir has completed a Phase 2 trial of TXL™, in which HBV-infected subjects were administered doses up to 100 mg for 28 days and is now optimizing its formulation to further enhance drug delivery. To date, TXL™ has achieved clinical proof of concept for antiviral activity and displayed an excellent safety, tolerability, and pharmacokinetic profile. Based on the agent’s best-in-class potential, ContraVir believes TXL™ can become the cornerstone of a curative combination therapy for hepatitis B.

About ContraVir Pharmaceuticals

ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted therapies for liver disease arising from chronic hepatitis B, C and D virus (HBV, HVC, HDV) and non-alcoholic steatohepatitis (NASH). The company is developing two novel anti-HBV compounds with complementary mechanisms of action.  TXL™, a direct acting antiviral (DAA) nucleotide analog lipid prodrug of tenofovir (TFV), is designed to deliver higher hepatic intracellular concentrations of the active tenofovir species (tenofovir diphosphate) while reducing concentrations of tenofovir outside the liver, causing fewer off-target toxicities and side-effects. CRV431, the other anti-HBV compound, is a host-targeting antiviral (HTA) next-generation cyclophilin inhibitor with a novel chemical structure that optimizes the selective index against HBV.  In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg), while offering additional benefits such as reducing liver fibrosis and hepatocellular carcinoma tumor burden. For more information, please visit

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on ContraVir’s current expectations and actual results could differ materially.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.  As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products.  There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful.  ContraVir does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in ContraVir’s Form 10-K for the year ended December 30, 2017 and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

Stephen Kilmer
ContraVir Investor Relations
(646) 274-3580


Tuesday, November 6, 2018 - 08:00